ReviewWorld journal of gastroenterology2014
Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 46 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pilot Randomized Controlled Trial of Spironolactone in Young Women With Nonalcoholic Steatohepatitis (NASH)
Phase 2A, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Saroglitazar Mg 4 mg Tablet Vs Placebo for Treating Nonalcoholic Fatty Liver Disease (NAFLD) in Women With Polycystic Ovary Syndrome (PCOS)
Who cites it
46 citing papers in PubMed, 4 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Non-alcoholic fatty liver disease across endocrinopathies: Interaction with sex hormones.Frontiers in endocrinology · 2022Pooled it
- Association between rs1800795 polymorphism in the interleukin-6 gene and the risk of polycystic ovary syndrome: A meta-analysis.Medicine · 2018Pooled it
- Effectiveness of Omega-3 fatty acid for polycystic ovary syndrome: a systematic review and meta-analysis.Reproductive biology and endocrinology : RB&E · 2018Pooled it
- Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis.Journal of endocrinological investigation · 2017Pooled it
- Sex Steroids Regulate Liver Fat Content and Body Fat Distribution in Both Men and Women: A Study in Transgender Persons.The Journal of clinical endocrinology and metabolism · 2023Trial
- The Interplay Between PMOS and MASLD: Pathophysiology and Evidence-Based Nutritional Interventions.Nutrients · 2026Review
- Hepatokines and polycystic ovary syndrome: investigating the connection between the hepato-ovarian axis and disorders in glycolipid metabolism in PCOS: a narrative review.Frontiers in endocrinology · 2026Review
- Sheep placental extract ameliorates polycystic ovary syndrome in rats by regulating ERβ-mediated Treg cells via the TGF-β1/Smad3 signaling pathway.Frontiers in immunology · 2026Article
- Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Clinical Implications and Therapeutic Advances.Endocrinology, diabetes & metabolism · 2025Review
- Association between liver function markers and menstrual cycle irregularity in Korean female population.Korean journal of family medicine · 2025Article
- Connecting the Dots: Mitochondrial Dysfunction, PCOS, and Insulin Resistance-Insights and Therapeutic Advances.International journal of molecular sciences · 2025Review
- Polycystic ovary syndrome as a metabolic disease.Nature reviews. Endocrinology · 2025Review
- [Metabolic-associated fatty liver disease (MAFLD): a multisystemic disease beyond the liver].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Review
- The role of traditional Chinese medicine in modulating gut microbiota to alleviating insulin resistance in polycystic ovary syndrome.Frontiers in nutrition · 2025Review
- Metabolic Implications of PCOS.Current pediatrics reports · 2025Article
- Metformin Alleviates Liver Metabolic Dysfunction in Polycystic Ovary Syndrome by Activating the Ethe1/Keap1/PINK1 Pathway.International journal of biological sciences · 2025Article
- Systematic low-grade chronic inflammation and intrinsic mechanisms in polycystic ovary syndrome.Frontiers in immunology · 2024Review
- Hepatic steatosis in women with polycystic ovary syndrome.BMC endocrine disorders · 2023Article
- Role of vascular endothelial growth factor B in nonalcoholic fatty liver disease and its potential value.World journal of hepatology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive-aged women. Women with PCOS frequently have metabolic complications including insulin resistance (IR), early diabetes, hypertension and dyslipidemia. Recent studies have demonstrated an association between PCOS and another metabolic complication: nonalcoholic fatty liver disease (NAFLD). NAFLD occurs as a result of abnormal lipid handling by the liver, which sensitizes the liver to injury and inflammation. It can progress to nonalcoholic steatohepatitis (NASH), which is characterized by hepatocyte injury and apoptosis. With time and further inflammation, NASH can progress to cirrhosis. Thus, given the young age at which NAFLD may occur in PCOS, these women may be at significant risk for progressive hepatic injury over the course of their lives. Many potential links between PCOS and NAFLD have been proposed, most notably IR and hyperandrogenemia. Further studies are needed to clarify the association between PCOS and NAFLD. In the interim, clinicians should be aware of this connection and consider screening for NAFLD in PCOS patients who have other metabolic risk factors. The optimal method of screening is unknown. However, measuring alanine aminotransferase and/or obtaining ultrasound on high-risk patients can be considered. First line treatment consists of lifestyle interventions and weight loss, with possible pharmacologic interventions in some cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.